1. Home
  2. VWAVW vs SCLXW Comparison

VWAVW vs SCLXW Comparison

Compare VWAVW & SCLXW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

VWAVW

VisionWave Holdings Inc. Warrant

N/A

Current Price

$1.30

Market Cap

0.0

Sector

Technology

ML Signal

N/A

Logo Scilex Holding Company

SCLXW

Scilex Holding Company

HOLD

Current Price

$0.14

Market Cap

0.0

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
VWAVW
SCLXW
Founded
2024
N/A
Country
United States
United States
Employees
N/A
31
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
N/A
N/A
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
VWAVW
SCLXW
Price
$1.30
$0.14
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
573.0K
4.0K
Earning Date
08-27-2025
03-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$55,152,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
22.02
52 Week Low
$0.06
$0.18
52 Week High
$0.48
$0.18

Technical Indicators

Market Signals
Indicator
VWAVW
SCLXW
Relative Strength Index (RSI) N/A 32.13
Support Level N/A $0.17
Resistance Level N/A $0.19
Average True Range (ATR) 0.00 0.03
MACD 0.00 -0.01
Stochastic Oscillator 0.00 0.28

Price Performance

Historical Comparison
VWAVW
SCLXW

About VWAVW VisionWave Holdings Inc. Warrant

VisionWave Holdings Inc is engaged in revolutionizing defense capabilities by integrating artificial intelligence (AI) and autonomous solutions across air, ground, and sea domains. Its innovations range from high-resolution radars and vision systems to radio frequency (RF) sensing technologies are seeking to redefine operational efficiency and precision for military and homeland security applications globally.

About SCLXW Scilex Holding Company

Scilex Holding Co is focused on acquiring, developing, and commercializing non-opioid pain management products for the treatment of acute and chronic pain. The Company's commercial product, ZTlido (lidocaine topical system), is a prescription lidocaine topical product for relieving pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain. It is focused on commercializing Gloperba (colchicine USP) an oral solution, a prophylactic treatment for painful gout flares in adults. The Company's three product candidates are SP-102 or SEMDEXA viscous gel formulation of a used corticosteroid for epidural injections, SP-103 a Phase 2, triple-strength formulation of ZTlido, and SP-104, 4.5 mg Delayed Burst Release Low Dose Naltrexone Hydrochloride (DBR-LDN) Capsule.

Share on Social Networks: